Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Downgraded by Zacks Investment Research

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday, Zacks.com reports.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI “

Separately, HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 12th.

ATNM traded up $0.13 on Monday, hitting $5.63. The company had a trading volume of 7,065 shares, compared to its average volume of 581,399. Actinium Pharmaceuticals has a 1 year low of $4.41 and a 1 year high of $10.30.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ACT Capital L.L.C. acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth about $332,000. Morgan Stanley grew its position in shares of Actinium Pharmaceuticals by 104.6% during the third quarter. Morgan Stanley now owns 43,972 shares of the biotechnology company’s stock worth $390,000 after buying an additional 22,483 shares in the last quarter. Marshall Wace LLP purchased a new stake in Actinium Pharmaceuticals during the third quarter worth approximately $199,000. GSA Capital Partners LLP lifted its stake in Actinium Pharmaceuticals by 44.8% during the third quarter. GSA Capital Partners LLP now owns 68,205 shares of the biotechnology company’s stock worth $604,000 after purchasing an additional 21,108 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Actinium Pharmaceuticals by 135.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 26,109 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 15,030 shares during the last quarter. 8.63% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals (Get Rating)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Recommended Stories

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.